| Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. | |
| | |
MedLine Citation:
|
PMID: 21149773 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To determine if prophylactic use of intraocular pressure (IOP)-lowering medication is effective in reducing the IOP spikes after intravitreal injections of pegaptanib, bevacizumab, and ranibizumab. METHODS: Seventy-one patients with exudative age-related macular degeneration received intravitreal injections of 1 of 3 anti-vascular endothelial growth factor medications: 30 patients received pegaptanib (0.09 mL), 47 patients received bevacizumab (0.05 mL), and 42 patients received ranibizumab (0.05 mL). Intraocular pressure-lowering medication, 1 hour prior to the injection, was used 63%, 74%, and 66% of the time in eyes that received pegaptanib, ranibizumab, and bevacizumab, respectively. Intraocular pressure was measured prior to injection, within 1 minute after injection, and every 5 to 10 minutes until the pressure was reduced to a safe level. RESULTS: All 3 intravitreal injections caused significant initial IOP spikes (mean [SD] IOP of 38.5 [11.56] mm Hg in the pegaptanib group, 37.75 [8.36] mm Hg in the ranibizumab group, and 34.88 [10.45] mm Hg in the bevacizumab group). The IOP reduced to less than 30 mm Hg in all 3 groups within 20 minutes. Prophylactic medication did not prevent postinjection IOP spikes. Patients with and without glaucoma showed a similar rate of IOP normalization over time in all 3 groups. CONCLUSION: Intraocular pressure spikes after intravitreal injection of pegaptanib, ranibizumab, and bevacizumab are common and in most cases transient. Routine prophylactic use of IOP-lowering medications is essentially ineffective in preventing IOP spikes after intravitreal injection of pegaptanib, ranibizumab, and bevacizumab and therefore not necessary before the injection. |
| | |
Authors:
|
Max P C Frenkel; Shamim A Haji; Ronald E P Frenkel |
Related Documents
:
|
18333493 - Acute effects of mk63 stun device discharges in miniature swine. 15694793 - Aneurysm sac pressure monitoring: effect of technique on interpretation of measurements. 18815843 - A randomized controlled trial of team-based care: impact of physician-pharmacist collab... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Archives of ophthalmology Volume: 128 ISSN: 1538-3601 ISO Abbreviation: Arch. Ophthalmol. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-14 Completed Date: 2011-01-14 Revised Date: 2011-04-26 |
Medline Journal Info:
|
Nlm Unique ID: 7706534 Medline TA: Arch Ophthalmol Country: United States |
Other Details:
|
Languages: eng Pagination: 1523-7 Citation Subset: AIM; IM |
Affiliation:
|
Eye Research Foundation, Stuart, FL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged, 80 and over Angiogenesis Inhibitors / administration & dosage, adverse effects* Antibodies, Monoclonal / administration & dosage, adverse effects Antihypertensive Agents / therapeutic use* Aptamers, Nucleotide / administration & dosage, adverse effects Female Humans Intraocular Pressure / drug effects* Intravitreal Injections Macular Degeneration / drug therapy Male Ocular Hypertension / chemically induced, drug therapy* Retrospective Studies Tonometry, Ocular Vascular Endothelial Growth Factor A / antagonists & inhibitors Visual Acuity |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antihypertensive Agents; 0/Aptamers, Nucleotide; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/bevacizumab; 0/pegaptanib; 0/ranibizumab |
| Comments/Corrections | |
Erratum In:
|
Arch Ophthalmol. 2011 Mar;129(3):275 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cryotherapy vs laser photocoagulation in scleral buckle surgery: A randomized clinical trial.
Next Document: Longitudinal and cross-sectional analyses of visual field progression in participants of the Ocular ...